atxi20250630

atxi20250630_10q.htm

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-38114

AVENUE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	47-4113275
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154

(Address of principal executive offices and zip code)

(781) 652‑4500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act: None

Securities registered pursuant to Section 12(g) of the Exchange Act:

Title of Class	Trading Symbol(s)
Common Stock	ATXI (OTC Markets Group, Inc.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date.

Class of Common Stock		Outstanding Shares as of August 12, 2025
Common Stock, $0.0001 par value		3,183,558

Table of Contents

AVENUE THERAPEUTICS, INC.

Form 10‑Q

For the Quarter Ended June 30, 2025

Table of Contents

		Page No.
PART I. FINANCIAL INFORMATION

Item 1.	Unaudited Condensed Consolidated Financial Statements	1

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	10

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	15

Item 4.	Controls and Procedures	15

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	16

Item 1A.	Risk Factors	16

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	16

Item 3.	Defaults Upon Senior Securities	16

Item 4.	Mine Safety Disclosures	16

Item 5.	Other Information	16

Item 6.	Exhibits	17

SIGNATURES		18

Table of Contents

AVENUE THERAPEUTICS, INC.

Unaudited Condensed Consolidated Balance Sheets

($ in thousands, except share and per share amounts)

	*June 30,*			*December 31,*
	*2025*			*2024*

ASSETS
Current assets:
Cash and cash equivalents	$	3,326		$	2,594
Prepaid expenses and other current assets		35			78
Receivable per license termination and transfer agreement		800			—
Total assets	$	4,161		$	2,672

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable and accrued expenses	$	952		$	654
Accounts payable and accrued expenses - related party		377			146
Warrant liability		—			16
Total current liabilities		1,329			816

Total liabilities		1,329			816

Commitments and contingencies (Note 6)

Stockholders’ equity
Preferred stock ($0.0001 par value), 2,000,000 shares authorized
Class A Preferred Stock, 250,000 shares issued and outstanding as of June 30, 2025 and December 31, 2024		—			—
Common stock ($0.0001 par value), 200,000,000 shares authorized
Common shares, 3,183,558 and 2,108,670 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively		—			—
Additional paid-in capital		108,155			105,377
Accumulated deficit		(104,097	)		(102,580	)
Total stockholders’ equity attributed to the Company		4,058			2,797

Non-controlling interests		(1,226	)		(941	)
Total stockholders’ equity		2,832			1,856
Total liabilities and stockholders’ equity	$	4,161		$	2,672

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

AVENUE THERAPEUTICS, INC.

Unaudited Condensed Consolidated Statements of Operations

($ in thousands, except share and per share amounts)

	*For the Three Months Ended June 30,*						*For the Six Months Ended June 30,*
	*2025*			*2024*			*2025*			*2024*
Revenue
Other revenue	$	1,404		$	—		$	1,404		$	—

Operating expenses:
Research and development		192			1,361			603			3,752
General and administrative		915			1,462			2,408			2,778
Total operating expenses		1,107			2,823			3,011			6,530
Income (loss) from operations		297			(2,823	)		(1,607	)		(6,530	)

Other income (expense):
Interest income		31			52			62			100
Loss on settlement of common stock warrant liabilities		—			(185	)		—			(759	)
Change in fair value of warrant liabilities		1			255			16			139
Total other income (expense)		32			122			78			(520	)
Net income (loss)	$	329		$	(2,701	)	$	(1,529	)	$	(7,050	)

Net loss attributable to non-controlling interests		(6	)		(9	)		(12	)		(18	)
Net income (loss) attributable to Avenue	$	335		$	(2,692	)	$	(1,517	)	$	(7,032	)

Net income (loss) attributable to common stockholders	$	335		$	(7,186	)	$	(1,517	)	$	(15,842	)

Net income (loss) per common share attributable to common stockholders, basic and diluted	$	0.11		$	(6.43	)	$	(0.49	)	$	(18.86	)

Weighted average number of common shares outstanding, basic and diluted		3,183,558			1,117,769			3,077,704			839,900

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

AVENUE THERAPEUTICS, INC.

Unaudited Condensed Consolidated Statement of Changes in Stockholders’ Equity

($ in thousands, except share amounts)

*Three months ended June 30, 2025*

	*Class A Preferred*									*Additional*						*Non-*			*Total*
	*Shares*				*Common Shares*					*Paid-in*			*Accumulated*			*Controlling*			*Stockholders’*
	*Shares*		*Amount*		*Shares*			*Amount*		*Capital*			*Deficit*			*Interests*			*Equity*
Balance at March 31, 2025		250,000	$	—		3,183,603		$	—	$	107,942		$	(104,432	)	$	(1,178	)	$	2,332
Share based compensation		—		—		(45	)		—		175			—			—			175
Shares receivable from AnnJi		—		—		—			—		(4	)		—			—			(4	)
Non-controlling interest in subsidiaries		—		—		—			—		42			—			(42	)		—
Net loss attributable to non-controlling interest		—		—		—			—		—			—			(6	)		(6	)
Net loss attributable to common stockholders		—		—		—			—		—			335			—			335
Balance at June 30, 2025		250,000	$	—		3,183,558		$	—	$	108,155		$	(104,097	)	$	(1,226	)	$	2,832

*Six Months Ended June 30, 2025*

	*Class A Preferred*								*Additional*						*Non-*			*Total*
	*Shares*				*Common Shares*				*Paid-in*			*Accumulated*			*Controlling*			*Stockholders’*
	*Shares*		*Amount*		*Shares*		*Amount*		*Capital*			*Deficit*			*Interests*			*Equity*
Balance at December 31, 2024		250,000	$	—		2,108,670	$	—	$	105,377		$	(102,580	)	$	(941	)	$	1,856
Share based compensation		—		—		239		—		360			—			—			360
Issuance of common stock to Fortress		—		—		135,659		—		55			—			—			55
Issuance of common stock, net of offering costs under open market sales agreement (ATM)		—		—		938,990		—		2,094			—			—			2,094
Shares receivable from AnnJi		—		—		—		—		(4	)		—			—			(4	)
Non-controlling interest in subsidiaries		—		—		—		—		273			—			(273	)		—
Net loss attributable to non-controlling interest		—		—		—		—		—			—			(12	)		(12	)
Net loss attributable to common stockholders		—		—		—		—		—			(1,517	)		—			(1,517	)
Balance at June 30, 2025		250,000	$	—		3,183,558	$	—	$	108,155		$	(104,097	)	$	(1,226	)	$	2,832

*Three months ended June 30, 2024*

	*Class A Preferred*								*Additional*						*Non-*			*Total*
	*Shares*				*Common Shares*				*Paid-in*			*Accumulated*			*Controlling*			*Stockholders’*
	*Shares*		*Amount*		*Shares*		*Amount*		*Capital*			*Deficit*			*Interests*			*Equity*
Balance at March 31, 2024		250,000	$	—		590,188	$	—	$	*98,104*		$	(95,268	)	$	(938	)	$	1,898
Share based compensation		—		—		—		—		192			—			—			192
Common shares issuable - Founders Agreement		—		—		—		—		(8	)		—			—			(8	)
Issuance of common stock to Fortress		—		—		25,567		—		172			—			—			172
Loss on settlement of common stock warrant liabilities		—		—		—		—		296			—			—			296
Exercise of warrants		—		—		402,768		—		4,448			—			—			4,448
Issuance of common stock, net of offering costs under open market sales agreement (ATM)		—		—		84,683		—		295			—			—			295
Warrant inducement offering costs		—		—		—		—		(765	)		—			—			(765	)
Reverse split (1-for-75)		—		—		86,518		—		—			—			—			—
Non-controlling interest in subsidiaries		—		—		—		—		(10	)		—			10			—
Net loss attributable to non-controlling interest		—		—		—		—		—			—			(9	)		(9	)
Net loss attributable to common stockholders		—		—		—		—		—			(2,692	)		—			(2,692	)
Balance at June 30, 2024		250,000	$	—		1,189,724	$	—	$	102,724		$	(97,960	)	$	(937	)	$	3,827

Six Months Ended June 30, 2024

Class A Preferred

Additional

Non-

Total

Shares

Common Shares

Paid-in

Accumulated

Controlling

Stockholders’

Shares

Amount

Shares

Amount

Capital

Deficit

Interests

Equity

Balance at December 31, 2023

250,000

—

341,324

92,507

(90,928

)

(928

)

654

Share based compensation

SEC Form 10-Q filed by Avenue Therapeutics Inc.